| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia (NCT07770698) | BeOne Medicines | 2026-10-01 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations (NCT07746141) | BeOne Medicines | 2026-09-04 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC (NCT07733180) | BeOne Medicines | 2026-08-31 |
| A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants (NCT07712640) | BeOne Medicines | 2026-07-21 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies (NCT07619287) | BeOne Medicines | 2026-06-23 |
| A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults (NCT07628881) | BeOne Medicines | 2026-06-17 |
| A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) (NCT07652736) | BeOne Medicines | 2026-06-05 |
| A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants (NCT07590102) | BeOne Medicines | 2026-06-04 |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (NCT07492641) | BeOne Medicines | 2026-05-22 |
| A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States (NCT07554521) | BeOne Medicines | 2026-04-30 |
| A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors (NCT07414836) | BeOne Medicines | 2026-04-13 |
| A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases (NCT07412691) | BeOne Medicines | 2026-03-19 |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (NCT07277231) | BeOne Medicines | 2026-01-22 |
| A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors (NCT07226349) | BeOne Medicines | 2025-12-11 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (NCT07222267) | BeOne Medicines | 2025-12-11 |
| A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (NCT07181681) | BeOne Medicines | 2025-11-10 |
| A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (NCT07141511) | BeOne Medicines | 2025-09-24 |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT06973187) | BeOne Medicines | 2025-09-04 |
| A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07043400) | BeOne Medicines | 2025-08-27 |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (NCT06943872) | BeOne Medicines | 2025-06-11 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (NCT06970743) | BeOne Medicines | 2025-05-29 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors (NCT06846671) | BeOne Medicines | 2025-04-10 |
| A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors (NCT06803680) | BeOne Medicines | 2025-03-18 |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) (NCT06742996) | BeOne Medicines | 2025-03-05 |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (NCT06756932) | BeOne Medicines | 2025-02-04 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (NCT06697184) | BeOne Medicines | 2025-01-23 |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (NCT06589596) | BeOne Medicines | 2025-01-10 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (NCT06585488) | BeOne Medicines | 2024-12-13 |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors (NCT06625593) | BeOne Medicines | 2024-12-09 |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT06685718) | BeOne Medicines | 2024-12-05 |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (NCT06634589) | BeOne Medicines | 2024-11-27 |
| A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia (NCT06637501) | BeOne Medicines | 2024-11-14 |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (NCT06598800) | BeOne Medicines | 2024-10-18 |
| An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (NCT06568614) | BeOne Medicines | 2024-10-12 |
| A Study of BG-C477 in Participants With Advanced Solid Tumors (NCT06596473) | BeOne Medicines | 2024-10-03 |
| A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors (NCT06427941) | BeOne Medicines | 2024-07-23 |
| A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors (NCT06487858) | BeOne Medicines | 2024-07-16 |
| A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT06422520) | BeOne Medicines | 2024-07-08 |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (NCT06233942) | BeOne Medicines | 2024-04-12 |
| BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (NCT06253195) | BeOne Medicines | 2024-04-01 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors (NCT06120283) | BeOne Medicines | 2023-12-01 |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT06073821) | BeOne Medicines | 2023-11-11 |
| A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (NCT05952037) | BeOne Medicines | 2023-10-23 |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT05981703) | BeOne Medicines | 2023-09-21 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (NCT05828589) | BeOne Medicines | 2023-06-20 |
| A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy (NCT05707377) | BeOne Medicines | 2023-04-17 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (NCT05100862) | BeOne Medicines | 2022-03-10 |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (NCT04973605) | BeOne Medicines | 2021-09-16 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| A Study of BGB-11417 in Participants With Myeloid Malignancies (NCT04771130) | BeOne Medicines | 2021-05-24 |
| Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies (NCT04277637) | BeOne Medicines | 2020-03-24 |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (NCT04164199) | BeOne Medicines | 2019-12-19 |
| A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation (NCT04002297) | BeOne Medicines | 2019-08-20 |